Climb Bio Inc (CLYM) Stock Price, Quote & News

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 857 2596

Website: climbbio.com

Address:

20 William Street, Suite 145, Wellesley Hills, United States

Gtrading1234 Feb. 21 at 2:18 AM

$CLYM

0 · Reply

FoxySprout Feb. 20 at 1:17 PM

$CLYM

0 · Reply

BillionerOfKing Feb. 19 at 8:28 PM

$CLYM Current Stock Price: $5.66 Contracts to trade: $5.0 CLYM Feb 20 2026 Call Entry: $0.68 Exit: $0.99 ROI: 47% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

QuietLoom Feb. 18 at 7:09 AM

$CLYM CLYM or unknown micro-cap with minimal public information and likely illiquid.

0 · Reply

Trigga_tha_Gambler Feb. 13 at 8:34 PM

$CLYM In at 5.64

0 · Reply

SMART4TRADER Feb. 13 at 6:26 PM

$ASTI $CLYM $HYMC How to find the top 1% of assets Guide to Trend Momentum Screener in Tr... https://youtu.be/CUMND83J218?si=Xju9nnxJ0tMTZ4Le #Stocks #investing #stockmarkets

0 · Reply

John_week Feb. 13 at 2:27 PM

$CLYM we go to 23 dolla

0 · Reply

notreload_ai Feb. 13 at 1:31 PM

Piper Sandler launches coverage of biotech $CLYM with an Overweight rating and $23 price target, highlighting its promising pipeline and key catalysts expected in 2026. https://notreload.xyz/piper-sandler-starts-coverage-on-climb-bio-with-bullish-outlook/

0 · Reply

Quantumup Feb. 13 at 1:04 PM

Piper Sandler🏁 $CLYM and said, We are initiating coverage on Climb Bio, Inc. (CLYM) with an OW rating and $23 PT where it is developing budoprutug (anti-CD19) across three indications (pMN, ITP, SLE) and CLYM116 (anti-APRIL) in IgAN. $CGEM $ZBIO $NVS $SNY TAK ARGX Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2022294106731376962?s=20

0 · Reply

YouVSYou Feb. 10 at 2:52 AM

Potential swing watchlist Wait for triggers and set alerts 🌟 $CLYM pullback 5.36 Daily chart setup stochastic 4 hour break 5.88/6.31/7 $WULF pullback $16 Retest 17.74/19.88/22 13.88 ideal $UMAC Perfect bounce off demand 10.76 15.40 next test $LUNR daily chart setup stochastic Keybreak 19.35 23/27 above $ONDS 11.85 next target Gap above 13.79 8.42 was A+ Potential Swing watchlist alerts set at price points any chart or levels Tag me

0 · Reply

Climb Bio to Present at Upcoming Investor Conferences

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Nov 25, 2025, 7:00 AM EST - 3 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 7:01 AM EST - 3 months ago

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 21, 2025, 7:00 AM EDT - 4 months ago

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 17, 2025, 7:00 AM EDT - 4 months ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Sep 29, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 4, 2025, 7:00 AM EDT - 6 months ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Aug 25, 2025, 2:41 PM EDT - 6 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 6 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 10 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:00 AM EDT - 11 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 11 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 7:00 AM EST - 1 year ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 4, 2025, 7:00 AM EST - 1 year ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 7:00 AM EST - 1 year ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Dec 19, 2024, 7:00 AM EST - 1 year ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

May 11, 2023, 4:10 PM EDT - 3 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 3 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Feb 9, 2023, 4:01 PM EST - 3 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Gtrading1234 Feb. 21 at 2:18 AM

$CLYM

0 · Reply

FoxySprout Feb. 20 at 1:17 PM

$CLYM

0 · Reply

BillionerOfKing Feb. 19 at 8:28 PM

0 · Reply

QuietLoom Feb. 18 at 7:09 AM

$CLYM CLYM or unknown micro-cap with minimal public information and likely illiquid.

0 · Reply

Trigga_tha_Gambler Feb. 13 at 8:34 PM

$CLYM In at 5.64

0 · Reply

SMART4TRADER Feb. 13 at 6:26 PM

$ASTI $CLYM $HYMC How to find the top 1% of assets Guide to Trend Momentum Screener in Tr... https://youtu.be/CUMND83J218?si=Xju9nnxJ0tMTZ4Le #Stocks #investing #stockmarkets

0 · Reply

John_week Feb. 13 at 2:27 PM

$CLYM we go to 23 dolla

0 · Reply

notreload_ai Feb. 13 at 1:31 PM

0 · Reply

Quantumup Feb. 13 at 1:04 PM

0 · Reply

YouVSYou Feb. 10 at 2:52 AM

0 · Reply

BillionerOfKing Feb. 6 at 3:29 AM

$CLYM Current Stock Price: $4.64 Contracts to trade: $5.0 CLYM Feb 20 2026 Call Entry: $0.58 Exit: $1.11 ROI: 92% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

HIGHTABLETRADES Feb. 4 at 3:11 PM

$CLYM $XBI $SPY THIS is breaking out of this triangle. https://climbbio.com/

1 · Reply

HIGHTABLETRADES Feb. 4 at 2:58 PM

$CLYM I like this. See small arrow

0 · Reply

HIGHTABLETRADES Feb. 4 at 2:52 PM

$CLYM added 100 shares

0 · Reply

MilaFoster Feb. 2 at 6:42 PM

$CLYM thin speculative tape coiling tight with asymmetry

0 · Reply

DunnoT Jan. 23 at 8:18 AM

$CLYM called it

0 · Reply

youspeaktome Jan. 22 at 4:37 PM

$CLYM here it comes

0 · Reply

kubota2323 Jan. 20 at 4:00 PM

$CLYM $CRVS $MRAM legs go.

0 · Reply

kubota2323 Jan. 20 at 3:56 PM

$CLYM RA CAPITAL MANAGEMENT, L.P. 46.37% VANGUARD GROUP INC 1.94% Affinity Asset Advisors, LLC 1.92% Kynam Capital Management, LP 1.52% TANG CAPITAL MANAGEMENT LLC 1.48% BlackRock, Inc. 1.09% Peapod Lane Capital LLC 0.83% CANTOR FITZGERALD, L. P. 0.81% RENAISSANCE TECHNOLOGIES LLC 0.79% PRICE T ROWE ASSOCIATES INC /MD/ 0.78%

0 · Reply

kubota2323 Jan. 20 at 3:16 PM

$CLYM added/adding

0 · Reply

Ramanda87 Jan. 10 at 8:08 PM

$CLYM 5,200 shares at an avg of $2.32 and accumulating. How high can this go 2026? $10? $20? $30? And why?

0 · Reply

MikeCaymanTrades Jan. 9 at 9:24 PM

$CLYM Breakout Dec. Dropped and a huge bounce from 3.50

0 · Reply

Market Cap	383.88M
Revenue (ttm)	0.00
Net Income (ttm)	-73.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	416,200
Avg Vol	1,493,416
Day's Range	N/A - N/A
Shares Out	68.18M
Stochastic %K	67%
Beta	-0.15
Analysts	Strong Sell
Price Target	$11.43